Accelerating Antibody Therapeutic Development

Fc effector function profiling uncovers what neutralization misses, driving smarter candidate selection.

By screening antibodies beyond neutralization, Fc profiling revealed immune mechanisms like phagocytosis and NK cell activation that contribute to in vivo efficacy. This approach helped identify polyfunctional antibodies earlier in the pipeline—giving developers a functional lens to prioritize candidates with greater therapeutic potential.

• Exposed functional differences not seen in neutralization assays
• Delivered early insight into effector mechanisms linked to protection
• Enabled faster, data-driven down-selection of clinically promising mAbs